UK Markets closed

GlaxoSmithKline plc (GSK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
29.43+0.07 (+0.24%)
At close: 04:00PM EDT
29.50 +0.07 (+0.24%)
After hours: 07:57PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.25
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 346.97
52-week low 328.47
50-day moving average 334.93
200-day moving average 341.47

Share statistics

Avg vol (3-month) 36.87M
Avg vol (10-day) 37.93M
Shares outstanding 52.52B
Implied shares outstanding 6N/A
Float 81.96B
% held by insiders 10.03%
% held by institutions 110.81%
Shares short (14 Jul 2022) 45.57M
Short ratio (14 Jul 2022) 41.28
Short % of float (14 Jul 2022) 4N/A
Short % of shares outstanding (14 Jul 2022) 40.27%
Shares short (prior month 14 Jun 2022) 47.11M

Dividends & splits

Forward annual dividend rate 42.48
Forward annual dividend yield 45.89%
Trailing annual dividend rate 30.80
Trailing annual dividend yield 32.72%
5-year average dividend yield 45.25
Payout ratio 481.99%
Dividend date 305 Oct 2022
Ex-dividend date 418 May 2022
Last split factor 22:1
Last split date 311 Nov 1991

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022


Profit margin 12.24%
Operating margin (ttm)23.48%

Management effectiveness

Return on assets (ttm)6.58%
Return on equity (ttm)24.71%

Income statement

Revenue (ttm)37.24B
Revenue per share (ttm)18.56
Quarterly revenue growth (yoy)18.70%
Gross profit (ttm)22.66B
Net income avi to common (ttm)4.57B
Diluted EPS (ttm)2.88
Quarterly earnings growth (yoy)-39.90%

Balance sheet

Total cash (mrq)6.53B
Total cash per share (mrq)3.24
Total debt (mrq)22.11B
Total debt/equity (mrq)97.67
Current ratio (mrq)1.43
Book value per share (mrq)5.94

Cash flow statement

Operating cash flow (ttm)10.51B
Levered free cash flow (ttm)-9.89B